Tricuspid valve replacement is not a common operation and, in most series, is associated with high postoperative mortality. Although bioprosthetic valves appear to have improved the performance early after surgery, these valves will inevitably experience wear and degeneration, requiring a second implant. Redo valve surgery for bioprosthetic valve failure is challenging. In this context, there has been an understandable interest in percutaneous valve therapy to extend the life span of failing tricuspid valve prostheses. We briefly discuss in this chapter some technical issues and the first results of these new techniques of implant of orthotopic and heterotopic tricuspid valve. A long-term follow-up and large series are needed to improve these percutaneous approaches, but they are other weapons in the hands of the cardiologist to treat many patients with important co-morbidities, heart failure and high risk for surgical repair.
|Title of host publication||The Tricuspid Valve in Congenital Heart Disease|
|Publisher||Springer-Verlag Italia s.r.l.|
|Number of pages||9|
|ISBN (Print)||9788847054004, 8847053994, 9788847053991|
|Publication status||Published - Feb 1 2014|
ASJC Scopus subject areas